Loading...
The Food and Drug Administration approved polidocanol for sclerotherapy of small veins earlier in 2010; the product will soon become available. In France, where this drug has been available for years, a multicenter patient registry was established to assess polidocanol's clinical safety. In a study sponsored by the drug's maker, all 1605 patients who received at least one polidocanol treatment in a 4-year period were enrolled and surveyed; 59% were followed for at least 24 months. Adverse events that were considered likely to be polidocanol-related were recorded.
Of 6444 treatment sessions, 6284 involved polidocanol exclusively. Foam polidocanol was used in two thirds of treatment sessions. Varicose veins were treated in 81% of treatment ses…